

Wassim H Fares

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2137396/publications.pdf>

Version: 2024-02-01

57
papers

816
citations

623734

14
h-index

552781

26
g-index

57
all docs

57
docs citations

57
times ranked

1395
citing authors

#	ARTICLE	IF	CITATIONS
1	Pulmonary Hypertension in Obstructive Sleep Apnea: Is it Clinically Significant? a Critical Analysis of the Association and Pathophysiology. <i>Pulmonary Circulation</i> , 2015, 5, 220-227.	1.7	85
2	Mitochondrial dysfunction and pulmonary hypertension: cause, effect, or both. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2018, 314, L782-L796.	2.9	71
3	Dysfunctional BMPR2 signaling drives an abnormal endothelial requirement for glutamine in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2017, 7, 186-199.	1.7	57
4	Netrin-1 Regulates Fibrocyte Accumulation in the Decellularized Fibrotic Sclerodermatous Lung Microenvironment and in Bleomycin-Induced Pulmonary Fibrosis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1251-1261.	5.6	51
5	Usefulness of hyperbaric oxygen therapy to inhibit restenosis after percutaneous coronary intervention for acute myocardial infarction or unstable angina pectoris. <i>American Journal of Cardiology</i> , 2004, 93, 1533-1535.	1.6	50
6	Plexin C1 deficiency permits synaptotagmin 7-mediated macrophage migration and enhances mammalian lung fibrosis. <i>FASEB Journal</i> , 2016, 30, 4056-4070.	0.5	50
7	Thermodilution and Fick Cardiac Outputs Differ: Impact on Pulmonary Hypertension Evaluation. <i>Canadian Respiratory Journal</i> , 2012, 19, 261-266.	1.6	41
8	Pulmonary hypertension: diagnostic and therapeutic challenges. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 1221.	2.0	32
9	Right atrial pressure/pulmonary artery wedge pressure ratio: A more specific predictor of survival in pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 760-767.	0.6	22
10	A systematic review of transition studies of pulmonary arterial hypertension specific medications. <i>Pulmonary Circulation</i> , 2017, 7, 326-338.	1.7	22
11	Pulmonary hypertension in patients with interstitial lung disease. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 50, 38-46.	2.6	21
12	Management of Right Heart Failure in the Intensive Care Unit. <i>Clinics in Chest Medicine</i> , 2015, 36, 511-520.	2.1	20
13	S100A12 as a marker of worse cardiac output and mortality in pulmonary hypertension. <i>Respirology</i> , 2018, 23, 771-779.	2.3	18
14	Pulmonary arterial hypertension in the setting of scleroderma is different than in the setting of lupus: A review. <i>Respiratory Medicine</i> , 2018, 134, 42-46.	2.9	18
15	Hypercoagulability in Pulmonary Hypertension. <i>Clinics in Chest Medicine</i> , 2018, 39, 595-603.	2.1	18
16	Macitentan for the treatment of pulmonary arterial hypertension. <i>Vascular Health and Risk Management</i> , 2014, 10, 665.	2.3	17
17	Superior vena cava syndrome secondary to saphenous venous graft aneurysm with right atrial fistula. <i>Catheterization and Cardiovascular Interventions</i> , 2003, 60, 45-47.	1.7	14
18	Pulmonary Hypertension Prevalence and Prognosis in a Cohort of Patients with Hereditary Hemorrhagic Telangiectasia Undergoing Embolization of Pulmonary Arteriovenous Malformations. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 1353-1356.	5.6	14

#	ARTICLE	IF	CITATIONS
19	Risk factors for presence and severity of pulmonary embolism in patients with deep venous thrombosis. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2018, 6, 7-12.	1.6	14
20	Persistent left superior vena cava identified during central line placement: A case report. <i>Respiratory Medicine CME</i> , 2011, 4, 141-143.	0.1	13
21	Standard Nonspecific Therapies in the Management of Pulmonary Arterial Hypertension. <i>Clinics in Chest Medicine</i> , 2013, 34, 799-810.	2.1	13
22	Targeted approaches to the treatment of pulmonary hypertension. <i>Therapeutic Advances in Respiratory Disease</i> , 2012, 6, 147-159.	2.6	12
23	Lupus-Associated Pulmonary Arterial Hypertension: Variable Course and Importance of Prompt Recognition. <i>Case Reports in Medicine</i> , 2015, 2015, 1-5.	0.7	11
24	Review of the Ongoing Story of Appetite Suppressants, Serotonin Pathway, and Pulmonary Vascular Disease. <i>American Journal of Cardiology</i> , 2016, 117, 1691-1696.	1.6	11
25	Inhibition of restenosis by hyperbaric oxygen. <i>Cardiovascular Radiation Medicine</i> , 2002, 3, 124-126.	0.6	10
26	Complexity of macrophage migration inhibitory factor (MIF) and other angiogenic biomarkers profiling in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2017, 7, 730-733.	1.7	10
27	Unresolved pulmonary embolism leading to a diagnosis of pulmonary artery sarcoma. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2014, 43, 574-576.	1.6	9
28	Endovascular Treatment of a Large Iliac Vein Aneurysm and High-Flow Arteriovenous Fistula. <i>Annals of Vascular Surgery</i> , 2018, 53, 266.e5-266.e7.	0.9	9
29	Safety and Feasibility of Obtaining Wedged Pulmonary Artery Samples and Differential Distribution of Biomarkers in Pulmonary Hypertension. <i>Pulmonary Circulation</i> , 2012, 2, 477-482.	1.7	7
30	Orenitram . . . Not Verified. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 713-714.	5.6	7
31	A 49-Year-Old Man with Subacute Respiratory Failure and Interstitial Lung Opacities. <i>American Journal of Case Reports</i> , 2017, 18, 941-944.	0.8	7
32	Management of acute decompensated heart failure in an evidence-based era: What is the evidence behind the current standard of care?. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2008, 37, 173-178.	1.6	6
33	The "availability" bias: underappreciated but with major potential implications. <i>Critical Care</i> , 2014, 18, 118.	5.8	6
34	Hospitalizations with hereditary hemorrhagic telangiectasia and pulmonary hypertension in the United States from 2000 to 2014. <i>Respiratory Medicine</i> , 2019, 147, 26-30.	2.9	6
35	Reduced RVSWI Is Associated With Increased Mortality in Connective Tissue Disease Associated Pulmonary Arterial Hypertension. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 77.	2.4	6
36	Chronic Right Heart Failure. <i>Heart Failure Clinics</i> , 2018, 14, 413-423.	2.1	5

#	ARTICLE	IF	CITATIONS
37	The relationship between positive end-expiratory pressure and cardiac index in patients with acute respiratory distress syndrome. <i>Journal of Critical Care</i> , 2013, 28, 992-997.	2.2	4
38	Do single or sequential measurements of leptin and adiponectin in plasma have prognostic value in pulmonary arterial hypertension?. <i>Pulmonary Circulation</i> , 2017, 7, 727-729.	1.7	4
39	Is hyponatremia associated with mortality in pulmonary arterial hypertension?. <i>Pulmonary Circulation</i> , 2018, 8, 1-7.	1.7	4
40	The Assessment of the Right Heart Failure Syndrome. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2015, 36, 934-942.	2.1	3
41	Amiodarone and the risk of cancer: A nationwide population-based study. <i>Cancer</i> , 2013, 119, 4051-4051.	4.1	2
42	The Other Vascular Beds in Pulmonary Arterial Hypertension. Surrogates or Associated?. <i>Annals of the American Thoracic Society</i> , 2014, 11, 596-597.	3.2	2
43	Chronic Thromboembolic Pulmonary Hypertension: A Worldwide View of How Far We Have Come. <i>Lung</i> , 2016, 194, 483-485.	3.3	2
44	Reply: Oral Treprostinil Combination Trials Post Hoc Secondary Analyses: A Step toward Verifying Its Efficacy. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 193, 1437-1438.	5.6	2
45	Characteristics of provoked deep venous thrombosis in a tertiary care center. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2017, 5, 477-484.	1.6	2
46	Novel Mechanisms of Disease: Network Biology and MicroRNA Signaling in Pulmonary Hypertension. , 2016, , 123-133.		2
47	Should beta-blockers be discontinued when a patient is admitted to the hospital with acutely decompensated heart failure?. <i>Cleveland Clinic Journal of Medicine</i> , 2006, 73, 557-559.	1.3	2
48	Pulmonary Hypertension: Clinical Presentation, Diagnosis, Treatment, and Dana Point World Symposium Highlights. <i>Current Respiratory Medicine Reviews</i> , 2011, 7, 279-288.	0.2	1
49	Not All Catheter-Days Are Equal. <i>Critical Care Medicine</i> , 2013, 41, e14.	0.9	1
50	Pushing the Envelope on the Indications and Doses of Pulmonary Arterial Hypertension Medications. <i>Journal of Cardiovascular Pharmacology</i> , 2016, 67, 319-321.	1.9	1
51	PECAM-1 is Associated With Outcomes and Response to Treatment in Pulmonary Arterial Hypertension. <i>American Journal of Cardiology</i> , 2020, 127, 198-199.	1.6	1
52	Controversies and Evolving Concepts in Critical Care. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2015, 36, 807-808.	2.1	0
53	Finally, Progress in Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2017, 56, 421-422.	2.9	0
54	Staged Endovascular Intervention of Bilateral Pulmonary Artery Stenosis. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 607-609.	2.9	0

#	ARTICLE	IF	CITATIONS
55	Reply. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2018, 6, 560-561.	1.6	0
56	Venous Thromboembolism: An Evolving Entity. <i>Clinics in Chest Medicine</i> , 2018, 39, xv-xvi.	2.1	0
57	Is postoperative atrial fibrillation in patients undergoing noncardiothoracic surgery an important problem? IMPACT consults. <i>Proceedings of the 2nd Annual Cleveland Clinic Perioperative Medicine Summit.. Cleveland Clinic Journal of Medicine</i> , 2006, 73, S20-S20.	1.3	0